Vicapsys Life Sciences, Inc.

What they do

Vicapsys Life Sciences, through its subsidiary ViCapsys, Inc., develops encapsulated product candidates incorporating proprietary derivatives of the chemokine CXCL12 to create an immunoprotective zone around cells, tissues, organs and devices. Its lead program, VICAPSYN, is an encapsulated human islet cell cluster intended to restore normal glucose control in Type 1 diabetes when implanted into the peritoneal cavity, licensed exclusively from Massachusetts General Hospital (MGH). A second line, VYBRIN, targets anti-fibrotic applications such as prevention of post-surgical abdominal adhesions, implant coating, and diabetic ulcer wound healing. The company has no revenues and operates as a holding company with no material assets other than its interest in ViCapsys.

Revenue drivers

• VICAPSYN (transplantation therapy) — Lead product candidate: encapsulated human islet cell clusters for Type 1 diabetes; preclinical, with no revenues, partnered academic research, and licensed exclusively from MGH.
• VYBRIN (anti-fibrotic applications) — Earlier-stage product line for post-surgical adhesion prevention, implantable device coating, and diabetic ulcer wound healing; no revenues.

Recent performance

The company generated no revenues for the three and nine months ended September 30, 2024 or 2023. Total operating expenses were $198,862 for the third quarter and $584,958 for the nine months ended September 30, 2024, versus $175,423 and $519,771 in the prior-year periods. The increase was driven by higher professional fees ($128,500 and $341,549 versus $76,050 and $240,303), partially offset by lower general and administrative costs after cancelling the D&O insurance policy in March 2024. Research and development spending remained minimal at $14,090 for the nine months, limited to MGH license and royalty fees. At September 30, 2024, the company had $89,569 in cash, an accumulated deficit of $17,052,745, and negative shareholder equity of $2.6 million.

Strategy

Management's stated strategy is to develop and commercialize intellectual property around CXCL12-based encapsulated products worldwide, with VICAPSYN the lead transplantation candidate and VYBRIN exploring anti-fibrotic applications. Preclinical and animal testing are required before filing an Investigational New Drug Application with the FDA, and the company acknowledges substantial additional equity, debt, collaborative, foundation, government or other funding is needed to reach that point. It has not met MGH license milestones, including submitting a business and development plan and raising $2 million by December 1, 2022 and an additional $8 million by December 1, 2023, and is negotiating extensions with MGH. Corporate partnerships are cited as necessary to move products into advanced clinical development and commercialization.

Risks

• Going-concern / near-term funding shortfall — Management states it does not have enough cash on hand to operate for the next 12 months and needs to raise an additional $1 million just to sustain base operations excluding development work.
• Unmet MGH license milestones — The company has not submitted its required business and development plan, has not raised the $2 million due December 2022, and has not raised the additional $8 million due December 2023, and is negotiating extensions with MGH.
• No revenue and no approved product — The company has recorded no revenues for the three and nine months ended September 30, 2024 or 2023, and its programs remain preclinical with an IND not yet filed.
• OTC Pink quotation with no established public trading market — The common stock is quoted on OTC Pink under VICP with no established public trading market, and disclosed bids were $1.00 throughout fiscal 2023, with the most recent private placement priced at $0.25 on April 12, 2023.

Outlook

Management states that substantial additional equity or debt financings, collaborative agreements, foundation or government grants, or other sources will be needed to complete preclinical and animal testing necessary to file an Investigational New Drug Application, and that further funding will be required to commence trials and regulatory activities. It estimates needing to raise an additional $1 million to sustain base operations over the next 12 months, excluding development work, and cautions there is no assurance it can obtain funding on commercially reasonable terms or at all. Additional capital is also cited as necessary for clinical development of the anti-fibrotic applications, with corporate partnerships deemed necessary for advanced development and commercialization. The company does not anticipate paying cash dividends in the foreseeable future.